

Overview of the FDA Product-Specific Guidance (PSG) Program

Christine Le, PharmD, PMP

Acting PSG Program Manager
Office of Research and Standards
Office of Generic Drugs | CDER | U.S. FDA

May 5, 2021


SBIA Webinar:

FDA Product-Specific Guidances: Lighting the Development Pathway for Generic Drugs

Outline

- PSG development processes
 - Collaborative efforts on how PSGs are prioritized, developed and published
- PSG webpages including the upcoming PSGs for complex generic drug product development webpage
- Public requests and bioequivalence (BE) comments

Product-Specific Guidance (PSG) Process



Prioritization for New PSG Development

- GDUFA commitments: Non-Complex NCEs
- Complexity of the product
- External interests: Pre-ANDA meetings, Controlled Correspondences, ANDAs without PSGs, Public Requests
- Public health priorities: COVID-19 pandemic, Opioid epidemic
- Drug availability and accessibility
 - Drug shortage, number of available products in market
 - Market share of the reference listed drug products
- Completion of research projects related to scientific gaps

NCE: New Chemical Entity

ANDA: Abbreviated New Drug Application

GDUFA: Generic Drug User Fee Amendments

How Revised PSGs are Planned?



Identification of Needs for PSG Revision

- Changes to the reference products: e.g., labeling update, supplements, new strength
- Newly identified safety concerns
- Consistency with revision to general guidances
- Responses to the received BE comments
- Citizen petitions
- New BE approaches from research: e.g., addition of the in vitro option
- New knowledge from ANDA assessments, Pre-ANDA meetings and controlled correspondences

Notification of PSG Revision*

Category	
Major	Additional BE studies or evidence recommended to support FDA approval
Minor	Any revision that is not considered major
Editorial	Non-substantive changes

*Upcoming PSGs for Complex Generic Drug Product Development:
<https://www.fda.gov/drugs/guidances-drugs/upcoming-product-specific-guidances-complex-generic-drug-product-development>

Public Requests for PSGs



- One of the sources is public requests for PSGs
 - The FDA receives approximately 100-150 requests annually
 - The FDA reviews these requests and takes appropriate action
- The public can submit requests to GenericDrugs@fda.hhs.gov

When are PSGs published?

- New and revised, draft PSGs are generally published quarterly in batches
- Some PSGs are published as a stand-alone PSG
 - Coordinate with citizen petition responses
 - Meet the GDUFA goal date
- The FDA will issue a notice in the Federal Register

FDA PSG Public Webpage



Product-Specific Guidances for Generic Drug Development

[f SHARE](#) [t TWEET](#) [in LINKEDIN](#) [p PIN IT](#) [e EMAIL](#) [p PRINT](#)

Disclaimer: Due to April 2019 systemwide upgrades to www.fda.gov, the filenames for product-specific guidances on this web page may not match the corresponding guidance titles. In such cases, the name on the document correctly identifies the title of the guidance. These discrepancies will be corrected as soon as possible.

To successfully develop and manufacture a generic drug product, an applicant should consider that their product is expected to be: pharmaceutically equivalent to its reference listed drug (RLD), i.e., to have the same active ingredient, dosage form, strength, and route of administration under the same conditions of use; bioequivalent to the RLD, i.e., to show no significant difference in the rate and extent of absorption of the active pharmaceutical ingredient; and, consequently, therapeutically equivalent, i.e., to be substitutable for the RLD with the expectation that the generic product will have the same safety and efficacy as its reference listed drug.

[Read more >>](#)

Total number of currently published PSGs: 1885

Product-Specific Guidances for Specific Products Arranged by Active Ingredient

[A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#)

Search by Active Ingredient or by RLD or RS Number

[Newly Added Guidances since March 2021](#)

[Newly Revised Guidances since March 2021](#)

Locating PSGs

Product-Specific Guidances for Generic Drug Development

Facebook Twitter LinkedIn YouTube RSS Email Print

Disclaimer: Due to April 2015 systemwide upgrades to www.fda.gov, the filenames for product-specific guidances on this web page may not match the corresponding guidance titles. In such cases, the name on the document correctly identifies the title of the guidance. These discrepancies will be corrected as soon as possible.

To successfully develop and manufacture a generic drug product, an applicant should consider that their product is expected to be: pharmaceutically equivalent to its reference listed drug (RLD), i.e., to have the same active ingredient, dosage form, strength, and route of administration under the same conditions of use; bioequivalent to the RLD, i.e., to show no significant difference in the rate and extent of absorption of the active pharmaceutical ingredient; and, consequently, therapeutically equivalent, i.e., to be substitutable for the RLD with the expectation that the generic product will have the same safety and efficacy as its reference listed drug.

[Read more >>](#)

Total number of currently published PSGs: 1885

Product-Specific Guidances for Specific Products Arranged by Active Ingredient

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search by Active Ingredient or by RLD or RS Number

Enter at least 3 characters

Search

Newly Added Guidances since March 2021

Excel CSV PDF

Show: 10 entries

Filter:

Active Ingredient (link to Specific Guidance)	Type	Route	Dosage Form	RLD or RS Number	Date Recommended
Bismethazole Acetate	Draft	Subcutaneous	Solution	210557	03/2021
Calcitriol	Draft	Oral	Caplet, Extended Release	209510	03/2021
Cysteamine Bitartrate	Draft	Oral	Granule, Delayed Release	213491	03/2021
Oxegiclin Acetate	Draft	Subcutaneous	Powder	022201	03/2021

Contains Nonbinding Recommendations

Draft - Not for Implementation

Draft Guidance on Vancosycin Hydrochloride

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of General Drugs.

Active Ingredient: Vancosycin hydrochloride

Dosage Form; Route: For solution, oral

Strengths: EQ 25 mg/mL, Base and EQ 50 mg/mL, Base

Recommended Study: Request for Waiver of in vivo Bioequivalence Study Requirements

Waiver option:

To qualify for a waiver of the in vivo bioequivalence study requirement under 21 CFR 320.22(b)(5), generic versions of vancosycin hydrochloride oral solution lot must contain the same active drug ingredient in the same concentration and dosage form as the reference listed drug. The fruit-flavored diluent must contain no inactive ingredient or other changes in its formulation that may significantly affect its systemic or local availability.

Analyte to measure: Not applicable

Bioequivalence based on (90% CI): Not applicable

Dissolution test method and sampling times: Not applicable

Recommended Nov. 2020



How to Use RLD/RS on the PSG Webpage?

Search by Active Ingredient or by RLD or RS Number

Enter at least 3 characters

Search

108 record(s) found for 'L'

Excel

CSV

PDF

Show 10 entries

Filter:

Active Ingredient (link to Specific Guidance)	Type	Route	Dosage Form	RLD or RS Number	Date Recommended
Levonorgestrel	Draft	Oral	Tablet	021045 021998	02/2011
Levonorgestrel	Draft	Intrauterine	Intrauterine Device	021225	01/2020
Levorphanol Tartrate	Draft	Oral	Tablet	008720	11/2020
Levothyroxine sodium	Draft	Oral	Capsules	021924	11/2018
Levothyroxine Sodium	Draft	Oral	Tablet	021116 021210 021301 021342 021402	12/2014

RLD: Reference Listed Drug
RS: Reference Standard

How to Use RLD/RS on the PSG Webpage?



- RLD/RS information helps to identify the product related to a specific PSG
 - Not a substitution for the Orange Book
- Use the Orange Book for:
 - Correct basis of ANDA submission
 - A PSG may cover multiple RLDs
 - ANDA applicant must identify RLD appropriately
 - Current RS
 - Information is correct on the PSG webpage when the PSG is posted but the RS may change over time
 - Use Orange Book to verify

[Guidance for Industry, Referencing Approved Drug Products in ANDA Submissions](https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm) (Oct. 2020)

<https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm>



Upcoming PSGs for Complex Generic Drug Product Development Webpage

- Describes the FDA's plans for issuing new and revised PSGs for complex generic drug products (as defined in the Generic Drug User Fee Amendments II Commitment Letter) in the next 12 months
- Enhances transparency in PSG development or revision plan for complex products
- Assists applicants in planning their development of complex generic drug products, which are typically more difficult to develop
- Is updated quarterly when a new PSG batch is posted

<https://www.fda.gov/drugs/guidances-drugs/upcoming-product-specific-guidances-complex-generic-drug-product-development>

Public Comments on PSGs



- The FDA issues a Federal Register notice announcing the availability of new and revised PSGs (Docket Number FDA-2007-D-0369)
- The notice will identify a comment period for the draft recommendations
- The FDA will consider comments on draft PSGs in developing final BE recommendations

PSGs Withdrawn

- Recommendations in a product-specific guidance are withdrawn when they no longer reflect the FDA's current thinking
- The withdrawal list can be accessed via:

<https://www.fda.gov/media/90032/download>

CDER Product-Specific Guidances Withdrawn Listing
Updated March 4, 2021

ACTIVE INGREDIENT	TYPE OF GUIDANCE	ROUTE AND DOSAGE FORM	RLD	DATE PSG POSTED	FEDERAL REGISTER NOTICE DATE
BUTENAFINE HYDROCHLORIDE	Draft	Topical cream	21408	3/1/2012	2/1/2015
LEVONORGESTREL	Draft	IUD	203159	4/1/2014	10/1/2014
THEOPHYLLINE	Draft	Oral Tablet, ER	081236, 089763, 089807, 089808	2/1/2010	8/28/2020
LORCASERIN HYDROCHLORIDE	Draft	Oral Tablet	022529	3/1/2015	3/4/2021
LORCASERIN HYDROCHLORIDE	Draft	Oral Tablet, ER	208524	5/1/2017	3/4/2021

Resources



- CDER Guidances Webpage:
<https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>
- [Guidance for Industry on Bioequivalence Recommendations for Specific Products](#) (June 2010)
- [Guidance for Industry, Referencing Approved Drug Products in ANDA Submissions](#) (Oct. 2020)
- PSGs for Generic Drug Development:
<https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm>
- Upcoming PSGs for Complex Generic Drug Product Development
<https://www.fda.gov/drugs/guidances-drugs/upcoming-product-specific-guidances-complex-generic-drug-product-development>

